GRI fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
GRI has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company